Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3041% below fair value

$1.00−0.02 (-1.96%)

Close on Nov 12, 2026Market cap $58.23MP/E –Yield –

Spero Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Spero Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Spero Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRO.

Revenue growth2.5% · median -46.5%

Operating margin-67.3% · median -181.3%

Net margin-71.0% · median -159.5%

Advertisement
300 × 250

See a number that looks wrong?